• Quarterly sales of $2.9 million, up 71% on prior period
• First US commercial contract signed for EasyScreen Gastrointestinal Parasite Detection Kit
• New strategy for automated, high throughput solutions through instrument customisation

Genetic Signatures Ltd reported sales of $2.9 million in Q3 FY2025, an increase of 71% on the prior corresponding period. This strong sales performance was primarily driven by high respiratory testing rates in Australia over the summer season. Receipts from customers for the quarter were $4.2 million, a 97.3% increase on the prior period. The company made significant progress in its US commercialisation efforts, signing its first commercial contract for the EasyScreen Gastrointestinal Parasite Detection Kit. Multiple customer sites are in various stages of procurement procedures. Genetic Signatures also continued to build inventory to support the anticipated initial stocking and sales orders.During the quarter, the company announced a new strategy to provide automated, high throughput solutions through the customisation of commercially available instruments. This approach will deliver a bespoke solution in a shorter timeframe and at a lower development cost compared to the previous direction. In parallel, Genetic Signatures is conducting a market assessment to expand its syndromic infectious disease menu for the 3base technology, which will be launched with the new hardware and software solution.The company's R&D team remains focused on improving existing workflows and increasing the automation and ease of operation of current instrumentation while the new solutions are being developed. Genetic Signatures ended the quarter with a strong cash balance of $37.4 million, providing continued support for the team and activities to achieve success in the US market and further innovation.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

Genetic Signatures remains focused on expanding its market presence, particularly in the US following FDA clearance, which is considered a key pillar of the growth strategy. The strong cash position enables continued support of the team and activities to achieve this success, as well as continuing to innovate in assay development, workflow enhancements and software.